This is a Validated Antibody Database (VAD) review about rat Cdk4, based on 52 published articles (read how Labome selects the articles), using Cdk4 antibody in all methods. It is aimed to help Labome visitors find the most suited Cdk4 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Cdk4 synonym: cyclin-dependent kinase 4; PSK-J3; cell division protein kinase 4

Invitrogen
mouse monoclonal (DCS-31)
  • immunohistochemistry - paraffin section; human; tbl 1
In order to determine the concordance between two methods to detect cases of atypical lipomatous tumor/well-differentiated liposarcoma, Invitrogen Cdk4 antibody (Invitrogen, AHZ0202) was used in immunohistochemistry - paraffin section on human samples (tbl 1). Am J Surg Pathol (2016) ncbi
mouse monoclonal (DCS-31)
  • western blot; rat; 1:1000; fig 4
In order to study the correlation between glutamate-induced neurotoxicity and expression of cell cycle proteins in cortical neurons, Invitrogen Cdk4 antibody (Invitrogen, AHZ0202) was used in western blot on rat samples at 1:1000 (fig 4). Biofactors (2016) ncbi
mouse monoclonal (DCS-35)
  • western blot; human; 1:1000; fig 2
In order to study prostate cancer DU145 cells and anti-tumor activity of the TRPM8 inhibitor BCTC, Invitrogen Cdk4 antibody (Neomarkers, MS-299-P0) was used in western blot on human samples at 1:1000 (fig 2). Oncol Lett (2016) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry; human; fig s4
In order to identify mutations in desmoplastic melanoma samples, Invitrogen Cdk4 antibody (Invitrogen, AHZ0202) was used in immunohistochemistry on human samples (fig s4). Nat Genet (2015) ncbi
mouse monoclonal (DCS-31)
  • western blot; human; fig 5
In order to analyze sensitivity to the cyclin D1/CDK4 pathway inhibition in Ewing sarcoma by a chemical genomic, functional, and super-enhancer screening, Invitrogen Cdk4 antibody (Thermo Fisher Scientific, MS-469-P0) was used in western blot on human samples (fig 5). Oncotarget (2015) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry; human
In order to investigate the frequency and contribution of HMGA2, CDK4, and JUN to dedifferentiated liposarcomas and atypical lipomatous tumors/well-differentiated liposarcomas, Invitrogen Cdk4 antibody (Biosource International, DCS 31) was used in immunohistochemistry on human samples . Mod Pathol (2015) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry - paraffin section; human; 1:50
In order to characterize a primary myxoid liposarcoma with chondroid and osseous components, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunohistochemistry - paraffin section on human samples at 1:50. Appl Immunohistochem Mol Morphol (2015) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry - paraffin section; human; 1:200
Invitrogen Cdk4 antibody (Invitrogen, clone DCS-31) was used in immunohistochemistry - paraffin section on human samples at 1:200. Hum Pathol (2015) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry - paraffin section; human; 1:100
In order to determine the role and diagnostic efficacy of RB1, CDK4, CHMP2B, HSP90, and cPLA2G4A as markers in myxofibrosarcomas and myxoid liposarcomas, Invitrogen Cdk4 antibody (Life Technologies, DCS-31) was used in immunohistochemistry - paraffin section on human samples at 1:100. Int J Surg Pathol (2014) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry; human
In order to describe a woman showing an incidental hibernoma associated with a cortical adenoma producing primary hyperaldosteronism, Invitrogen Cdk4 antibody (Biosource International, DCS-31) was used in immunohistochemistry on human samples . Pathol Res Pract (2013) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry; human; 1:700; tbl 1
In order to report on a case of plexiform fibromyxoma of the stomach, Invitrogen Cdk4 antibody (Invitrogen, DCS-31) was used in immunohistochemistry on human samples at 1:700 (tbl 1). Int J Surg Pathol (2014) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry - paraffin section; human; 1:200
Invitrogen Cdk4 antibody (Invitrogen, DCS-31) was used in immunohistochemistry - paraffin section on human samples at 1:200. World Neurosurg (2014) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry; human; 1:250; fig 4
In order to study the clinicopathological and genetic features of well-differentiated/dedifferentiated liposarcoma with prominent myxoid stroma, Invitrogen Cdk4 antibody (Invitrogen, DCS-31) was used in immunohistochemistry on human samples at 1:250 (fig 4). Histopathology (2013) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry; human; fig 3
In order to assess if MDM2 copy number distinguishes lipomas from atypical lipomatous tumors, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunohistochemistry on human samples (fig 3). Mod Pathol (2012) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry - paraffin section; human; 1:200; tbl 1.
In order to discuss markers that distinguish between different subtypes of osteosarcomas, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 1.). Am J Surg Pathol (2012) ncbi
mouse monoclonal (DCS-31)
  • immunocytochemistry; human; 1:250; fig 8
In order to characterize malignant fat-forming solitary fibrous tumor, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunocytochemistry on human samples at 1:250 (fig 8). Am J Surg Pathol (2011) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry; human; 1:50; fig 6
In order to examine expression of MDM2-CDK4 in low-grade osteosarcomas and fibrous or fibro-osseous lesions of the bone or paraosseous soft tissue, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunohistochemistry on human samples at 1:50 (fig 6). Mod Pathol (2011) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry - paraffin section; human; 1:200; fig 2
In order to use 9 cases of well-differentiated/dedifferentiated liposarcoma to characterize unappreciated features, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 2). Am J Surg Pathol (2010) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry - paraffin section; human; 1:200; fig 3
In order to explore the use of MDM2 and CDK4 for the histological diagnosis of low-grade osteosarcoma, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 3). Mod Pathol (2010) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry - paraffin section; human; 1:250; fig 6
In order to characterize 12 unusual liposarcomas, Invitrogen Cdk4 antibody (Biosource/Invitrogen, clone DCS-31) was used in immunohistochemistry - paraffin section on human samples at 1:250 (fig 6). Am J Surg Pathol (2010) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry; human; fig 3
In order to study the significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunohistochemistry on human samples (fig 3). Clin Cancer Res (2009) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry - paraffin section; human; 1:100
In order to report genetic changes in dedifferentiated liposarcomas, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunohistochemistry - paraffin section on human samples at 1:100. Mod Pathol (2009) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry; human; fig 2
In order to discuss a rare presentation of a lipoleiomyosarcoma and review the method of pathologic diagnosis, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunohistochemistry on human samples (fig 2). Am J Clin Oncol (2009) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry; human; tbl 2
In order to discuss the properties of desmoid tumors, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunohistochemistry on human samples (tbl 2). JOP (2008) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry - paraffin section; human; 1:100
In order to assess if immunostaining for PPAR-gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunohistochemistry - paraffin section on human samples at 1:100. Mod Pathol (2008) ncbi
mouse monoclonal (DCS-35)
  • immunoprecipitation; American mink
  • western blot; American mink
  • immunoprecipitation; scFv
In order to study if the growth state-dependent tyrosine phosphorylation of p27Kip1 determines whether or not it inhibits cdk4, Invitrogen Cdk4 antibody (NeoMarkers, DCS-35) was used in immunoprecipitation on American mink samples , in western blot on American mink samples and in immunoprecipitation on scFv samples . Mol Cell Biol (2008) ncbi
mouse monoclonal (DCS-31)
  • western blot; human
In order to elucidate how treatment with gallotannin prevents cancer, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in western blot on human samples . Mol Carcinog (2007) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry - paraffin section; human; 1:200; tbl 1
In order to present a unique case of relapsing retroperitoneal dedifferentiated liposarcoma with alpha-fetoprotein ectopic production, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 1). Virchows Arch (2006) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry - paraffin section; human; 1:400; tbl 1
In order to present the case of a patient with a rare atypical lipomatous tumor with spindle cell features, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunohistochemistry - paraffin section on human samples at 1:400 (tbl 1). Virchows Arch (2005) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry - frozen section; human; 1:200; fig 3
In order to characterize dedifferentiated liposarcomas with an inflammatory malignant fibrous histiocytoma component, Invitrogen Cdk4 antibody (Biosource International, clone DCS-31) was used in immunohistochemistry - frozen section on human samples at 1:200 (fig 3). J Pathol (2004) ncbi
mouse monoclonal (DCS-31)
  • western blot; mouse; fig 2
In order to report that cicaprost regulates the expression of Skp2, Invitrogen Cdk4 antibody (BioSource, DCS-31) was used in western blot on mouse samples (fig 2). J Biol Chem (2004) ncbi
mouse monoclonal (DCS-31)
  • immunohistochemistry - paraffin section; human
In order to report that most so-called malignant fibrous histiocytomas from the retroperitoneum are dedifferentiated liposarcoma, Invitrogen Cdk4 antibody (Biosource, DCS-31) was used in immunohistochemistry - paraffin section on human samples . Mod Pathol (2003) ncbi
Santa Cruz Biotechnology
mouse monoclonal (DCS-31)
  • western blot; human; loading ...; fig 2b
Santa Cruz Biotechnology Cdk4 antibody (SantaCruz, sc-56277) was used in western blot on human samples (fig 2b). Mol Cell (2017) ncbi
mouse monoclonal (97)
  • western blot; human; loading ...; fig 5c
Santa Cruz Biotechnology Cdk4 antibody (SantaCruz, sc-136241) was used in western blot on human samples (fig 5c). Oncogene (2017) ncbi
mouse monoclonal (3F121)
  • immunoprecipitation; human; 1:50; loading ...; fig 5f
  • western blot; human; loading ...; fig 5f
Santa Cruz Biotechnology Cdk4 antibody (Santa Cruz, sc-70831) was used in immunoprecipitation on human samples at 1:50 (fig 5f) and in western blot on human samples (fig 5f). Nat Commun (2017) ncbi
mouse monoclonal (DCS-35)
  • western blot; human; 1:200; loading ...; fig 5a
Santa Cruz Biotechnology Cdk4 antibody (Santa Cruz Biotechnology, sc-23896) was used in western blot on human samples at 1:200 (fig 5a). Oncotarget (2017) ncbi
mouse monoclonal (DCS-35)
  • western blot; human; 1:500; loading ...; fig 5h
Santa Cruz Biotechnology Cdk4 antibody (Santa Cruz, sc-23896) was used in western blot on human samples at 1:500 (fig 5h). Nat Commun (2017) ncbi
mouse monoclonal (3F121)
  • western blot; human; fig 2
Santa Cruz Biotechnology Cdk4 antibody (Santa Cruz, sc-70831) was used in western blot on human samples (fig 2). BMC Cancer (2016) ncbi
mouse monoclonal (DCS-31)
  • other; human; loading ...; fig st1
In order to use size exclusion chromatography-microsphere-based affinity proteomics to study clinical samples obtained from pediatric acute leukemia patients, Santa Cruz Biotechnology Cdk4 antibody (SCBT, DCS-31) was used in other on human samples (fig st1). Mol Cell Proteomics (2016) ncbi
mouse monoclonal (DCS-35)
  • western blot; human; 1:1000; fig 1
Santa Cruz Biotechnology Cdk4 antibody (Santa Cruz, SC23896) was used in western blot on human samples at 1:1000 (fig 1). Mol Med Rep (2015) ncbi
mouse monoclonal (DCS-35)
  • western blot; rat; 1:500; fig 3
Santa Cruz Biotechnology Cdk4 antibody (Santa Cruz, SC23896) was used in western blot on rat samples at 1:500 (fig 3). Int J Mol Med (2015) ncbi
mouse monoclonal (DCS-31)
  • western blot; human; 1:1000; fig 1
In order to analyze the anti-cancer effect of fucoidan on human colon cancer cells, Santa Cruz Biotechnology Cdk4 antibody (Santa Cruz Biotechnology, sc-56277) was used in western blot on human samples at 1:1000 (fig 1). Mol Med Rep (2015) ncbi
mouse monoclonal (DCS-35)
  • western blot; human; fig 7
Santa Cruz Biotechnology Cdk4 antibody (Santa Cruz, SC23896) was used in western blot on human samples (fig 7). PLoS ONE (2015) ncbi
mouse monoclonal (DCS-35)
  • western blot; human; fig 3
Santa Cruz Biotechnology Cdk4 antibody (Santa Cruz Biotechnology, sc-23896) was used in western blot on human samples (fig 3). Cell Cycle (2015) ncbi
mouse monoclonal (DCS-35)
  • western blot; human
Santa Cruz Biotechnology Cdk4 antibody (Santa Cruz Biotechnology, sc-23896) was used in western blot on human samples . BMC Cancer (2014) ncbi
mouse monoclonal (B-10)
  • western blot; human
Santa Cruz Biotechnology Cdk4 antibody (Santa Cruz, sc-166373) was used in western blot on human samples . Exp Cell Res (2014) ncbi
Abcam
rabbit monoclonal (EPR17525)
  • western blot; rat; 1:2000; loading ...; fig 6c
Abcam Cdk4 antibody (Abcam, ab199728) was used in western blot on rat samples at 1:2000 (fig 6c). Biosci Rep (2018) ncbi
Proteintech Group
rabbit polyclonal
  • western blot; human; loading ...; fig 2c
Proteintech Group Cdk4 antibody (Proteintech, 11026) was used in western blot on human samples (fig 2c). Tumour Biol (2016) ncbi
rabbit polyclonal
  • western blot; human; 1:1000; loading ...; fig 5
Proteintech Group Cdk4 antibody (Proteintech, 11026-1-AP) was used in western blot on human samples at 1:1000 (fig 5). Oncotarget (2015) ncbi
Novus Biologicals
rabbit polyclonal
  • immunohistochemistry - paraffin section; cat; 1:100; fig 5e
  • western blot; cat; 1:100; fig 4b
  • western blot; human; 1:100; loading ...; fig 4a
In order to elucidate how feline panleukopenia virus maintains host cells in the S phase, Novus Biologicals Cdk4 antibody (Novus Biologicals, NBP1-31308) was used in immunohistochemistry - paraffin section on cat samples at 1:100 (fig 5e), in western blot on cat samples at 1:100 (fig 4b) and in western blot on human samples at 1:100 (fig 4a). Cell Cycle (2016) ncbi
GeneTex
mouse monoclonal (DCS-31.2)
  • immunohistochemistry; human; 1:50
GeneTex Cdk4 antibody (GeneTex, GTX75694) was used in immunohistochemistry on human samples at 1:50. Pathol Res Pract (2014) ncbi
Sigma-Aldrich
mouse monoclonal (DCS-31)
  • western blot; human; fig 1b
In order to determine the effect of the hepatitis C viral load on host DNA damage, Sigma-Aldrich Cdk4 antibody (Sigma, C8218) was used in western blot on human samples (fig 1b). PLoS ONE (2017) ncbi
Articles Reviewed
  1. Jin L, Lu J, Gao J. Silencing SUMO2 promotes protection against degradation and apoptosis of nucleus pulposus cells through p53 signaling pathway in intervertebral disc degeneration. Biosci Rep. 2018;38: pubmed publisher
  2. Liao P, Zeng S, Zhou X, Chen T, Zhou F, Cao B, et al. Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding. Mol Cell. 2017;68:1134-1146.e6 pubmed publisher
  3. He D, Ren B, Liu S, Tan L, Cieply K, Tseng G, et al. Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies. Oncogene. 2017;36:3629-3639 pubmed publisher
  4. Li Z, Ivanov A, Su R, Gonzalez Pecchi V, Qi Q, Liu S, et al. The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies. Nat Commun. 2017;8:14356 pubmed publisher
  5. Graziano A, Cardile V, Avola R, Vicario N, Parenti C, Salvatorelli L, et al. Wilms' tumor gene 1 silencing inhibits proliferation of human osteosarcoma MG-63 cell line by cell cycle arrest and apoptosis activation. Oncotarget. 2017;8:13917-13931 pubmed publisher
  6. Liu T, Yu J, Deng M, Yin Y, Zhang H, Luo K, et al. CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. Nat Commun. 2017;8:13923 pubmed publisher
  7. Wang S, Lai K, Li C, Chiang C, Yu G, Sakamoto N, et al. The Paradoxical Effects of Different Hepatitis C Viral Loads on Host DNA Damage and Repair Abilities. PLoS ONE. 2017;12:e0164281 pubmed publisher
  8. Poncelet L, Garigliany M, Ando K, Franssen M, Desmecht D, Brion J. Cell cycle S phase markers are expressed in cerebral neuron nuclei of cats infected by the Feline Panleukopenia Virus. Cell Cycle. 2016;15:3482-3489 pubmed publisher
  9. Hrgovic I, Doll M, Kleemann J, Wang X, Zoeller N, Pinter A, et al. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. BMC Cancer. 2016;16:763 pubmed
  10. Clay M, Martinez A, Weiss S, Edgar M. MDM2 and CDK4 Immunohistochemistry: Should It Be Used in Problematic Differentiated Lipomatous Tumors?: A New Perspective. Am J Surg Pathol. 2016;40:1647-1652 pubmed
  11. Zhao Y, Zhang B, Lei Y, Sun J, Zhang Y, Yang S, et al. Knockdown of USP39 induces cell cycle arrest and apoptosis in melanoma. Tumour Biol. 2016;37:13167-13176 pubmed
  12. Negis Y, Karabay A. Expression of cell cycle proteins in cortical neurons-Correlation with glutamate-induced neurotoxicity. Biofactors. 2016;42:358-67 pubmed publisher
  13. Liu T, Fang Z, Wang G, Shi M, Wang X, Jiang K, et al. Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells. Oncol Lett. 2016;11:182-188 pubmed
  14. Kanderová V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, et al. High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics. 2016;15:1246-61 pubmed publisher
  15. Xu D, Wang J, Zhou Z, He Z, Zhao Q. Cannabinoid WIN55, 212-2 induces cell cycle arrest and inhibits the proliferation and migration of human BEL7402 hepatocellular carcinoma cells. Mol Med Rep. 2015;12:7963-70 pubmed publisher
  16. Shain A, Garrido M, Botton T, Talevich E, Yeh I, Sanborn J, et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet. 2015;47:1194-9 pubmed publisher
  17. Kennedy A, Vallurupalli M, Chen L, Crompton B, Cowley G, Vazquez F, et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget. 2015;6:30178-93 pubmed publisher
  18. Saâda Bouzid E, Burel Vandenbos F, Ranchère Vince D, Birtwisle Peyrottes I, Chetaille B, Bouvier C, et al. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas. Mod Pathol. 2015;28:1404-14 pubmed publisher
  19. Yan G, Wang Q, Hu S, Wang D, Qiao Y, Ma G, et al. Digoxin inhibits PDGF-BB-induced VSMC proliferation and migration through an increase in ILK signaling and attenuates neointima formation following carotid injury. Int J Mol Med. 2015;36:1001-11 pubmed publisher
  20. Han Y, Lee J, Lee S. Fucoidan inhibits the migration and proliferation of HT-29 human colon cancer cells via the phosphoinositide-3 kinase/Akt/mechanistic target of rapamycin pathways. Mol Med Rep. 2015;12:3446-3452 pubmed publisher
  21. Guha G, Lu W, Li S, Liang X, Kulesz Martin M, Mahmud T, et al. Novel Pactamycin Analogs Induce p53 Dependent Cell-Cycle Arrest at S-Phase in Human Head and Neck Squamous Cell Carcinoma (HNSCC) Cells. PLoS ONE. 2015;10:e0125322 pubmed publisher
  22. Weingertner N, Neuville A, Chibon F, Ray Coquard I, Marcellin L, Ghnassia J. Myxoid liposarcoma with heterologous components: dedifferentiation or metaplasia? A FISH-documented and CGH-documented case report. Appl Immunohistochem Mol Morphol. 2015;23:230-5 pubmed publisher
  23. Righi A, Gambarotti M, Benini S, Gamberi G, Cocchi S, Picci P, et al. MDM2 and CDK4 expression in periosteal osteosarcoma. Hum Pathol. 2015;46:549-53 pubmed publisher
  24. Meng D, Chen Y, Yun D, Zhao Y, Wang J, Xu T, et al. High expression of N-myc (and STAT) interactor predicts poor prognosis and promotes tumor growth in human glioblastoma. Oncotarget. 2015;6:4901-19 pubmed
  25. Bele A, Mirza S, Zhang Y, Ahmad Mir R, Lin S, Kim J, et al. The cell cycle regulator ecdysoneless cooperates with H-Ras to promote oncogenic transformation of human mammary epithelial cells. Cell Cycle. 2015;14:990-1000 pubmed publisher
  26. Oliveira C, de Bock C, Molloy T, Sadeqzadeh E, Geng X, Hersey P, et al. Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma. BMC Cancer. 2014;14:630 pubmed publisher
  27. Wang T, Goodman M, McGough R, Weiss K, Rao U. Immunohistochemical analysis of expressions of RB1, CDK4, HSP90, cPLA2G4A, and CHMP2B is helpful in distinction between myxofibrosarcoma and myxoid liposarcoma. Int J Surg Pathol. 2014;22:589-99 pubmed publisher
  28. Machado Neto J, Lazarini M, Favaro P, Franchi G, Nowill A, Saad S, et al. ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. Exp Cell Res. 2014;324:137-45 pubmed publisher
  29. Knösel T, Werner M, Jung A, Kirchner T, Dürr H. Dedifferentiated chondrosarcoma mimicking a giant cell tumor. Is this low grade dedifferentiated chondrosarcoma?. Pathol Res Pract. 2014;210:194-7 pubmed publisher
  30. Val Bernal J, Azueta A, Ortiz Rivas L, Fuentes J, Ballestero R. Incidental lipoma-like hibernoma arising from the adrenal gland: a well-differentiated liposarcoma mimicker. Pathol Res Pract. 2013;209:812-6 pubmed publisher
  31. Lee P, Yau D, Lau P, Chan J. Plexiform fibromyxoma (plexiform angiomyxoid myofibroblastic tumor) of stomach: an unusual presentation as a fistulating abscess. Int J Surg Pathol. 2014;22:286-90 pubmed publisher
  32. Yakkioui Y, Temel Y, Creytens D, Jahanshahi A, Fleischeuer R, Santegoeds R, et al. A comparison of cell-cycle markers in skull base and sacral chordomas. World Neurosurg. 2014;82:e311-8 pubmed publisher
  33. Sioletic S, Dal Cin P, Fletcher C, Hornick J. Well-differentiated and dedifferentiated liposarcomas with prominent myxoid stroma: analysis of 56 cases. Histopathology. 2013;62:287-93 pubmed publisher
  34. Kashima T, Halai D, Ye H, Hing S, Delaney D, Pollock R, et al. Sensitivity of MDM2 amplification and unexpected multiple faint alphoid 12 (alpha 12 satellite sequences) signals in atypical lipomatous tumor. Mod Pathol. 2012;25:1384-96 pubmed publisher
  35. Yoshida A, Ushiku T, Motoi T, Beppu Y, Fukayama M, Tsuda H, et al. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype. Am J Surg Pathol. 2012;36:423-31 pubmed publisher
  36. Lee J, Fletcher C. Malignant fat-forming solitary fibrous tumor (so-called "lipomatous hemangiopericytoma"): clinicopathologic analysis of 14 cases. Am J Surg Pathol. 2011;35:1177-85 pubmed publisher
  37. Dujardin F, Binh M, Bouvier C, Gomez Brouchet A, Larousserie F, Muret A, et al. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol. 2011;24:624-37 pubmed publisher
  38. Yoshida A, Ushiku T, Motoi T, Shibata T, Fukayama M, Tsuda H. Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant. Am J Surg Pathol. 2010;34:1361-6 pubmed publisher
  39. Yoshida A, Ushiku T, Motoi T, Shibata T, Beppu Y, Fukayama M, et al. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol. 2010;23:1279-88 pubmed publisher
  40. Mariño Enríquez A, Fletcher C, Dal Cin P, Hornick J. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria. Am J Surg Pathol. 2010;34:1122-31 pubmed publisher
  41. Italiano A, Bianchini L, Gjernes E, Keslair F, Ranchere Vince D, Dumollard J, et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res. 2009;15:5696-703 pubmed publisher
  42. Horvai A, Devries S, Roy R, O Donnell R, Waldman F. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol. 2009;22:1477-88 pubmed publisher
  43. Nahal A, Meterissian S. Lipoleiomyosarcoma of the rectosigmoid colon: a unique site for a rare variant of liposarcoma. Am J Clin Oncol. 2009;32:353-5 pubmed publisher
  44. Amiot A, Dokmak S, Sauvanet A, Vilgrain V, Bringuier P, Scoazec J, et al. Sporadic desmoid tumor. An exceptional cause of cystic pancreatic lesion. JOP. 2008;9:339-45 pubmed
  45. Horvai A, Schaefer J, Nakakura E, O Donnell R. Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. Mod Pathol. 2008;21:517-24 pubmed publisher
  46. James M, Ray A, Leznova D, Blain S. Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity. Mol Cell Biol. 2008;28:498-510 pubmed
  47. Al Ayyoubi S, Gali Muhtasib H. Differential apoptosis by gallotannin in human colon cancer cells with distinct p53 status. Mol Carcinog. 2007;46:176-86 pubmed
  48. Bosco M, Allia E, Coindre J, Odasso C, Pagani A, Pacchioni D. alpha-fetoprotein expression in a dedifferentiated liposarcoma. Virchows Arch. 2006;448:517-20 pubmed
  49. Mentzel T, Toennissen J, Rutten A, Schaller J. Palmar atypical lipomatous tumour with spindle cell features (well-differentiated spindle cell liposarcoma): a rare neoplasm arising in an unusual anatomical location. Virchows Arch. 2005;446:300-4 pubmed
  50. Coindre J, Hostein I, Maire G, Derré J, Guillou L, Leroux A, et al. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol. 2004;203:822-30 pubmed
  51. Stewart S, Kothapalli D, Yung Y, Assoian R. Antimitogenesis linked to regulation of Skp2 gene expression. J Biol Chem. 2004;279:29109-13 pubmed
  52. Coindre J, Mariani O, Chibon F, Mairal A, De Saint Aubain Somerhausen N, Favre Guillevin E, et al. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol. 2003;16:256-62 pubmed